Braveheart Bio Targets $1.2 Billion Valuation in IPO
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
Archive
Search
OpenAI Files Confidentially for a U.S. Initial Public Offering
The ChatGPT maker joined Anthropic in a high-stakes race to bring frontier AI companies to public markets.
Anthropic Confidentially Files for U.S. IPO
The Claude developer moved ahead of OpenAI as frontier AI companies prepare for public scrutiny.
Cerebras Shares Soar in $5.55 Billion Nasdaq Debut
The AI chipmaker nearly doubled its offering price as investors sought another route into compute infrastructure.
